Codexis to Participate in Upcoming Virtual Healthcare Conferences

Rhea-AI Summary

Codexis (Nasdaq:CDXS), an enzyme engineering leader, announced its participation in two virtual investment conferences. The H.C. Wainwright 23rd Annual Global Investment Conference will take place on September 13, 2021, featuring an on-demand corporate presentation. Following that, the Cantor Virtual Global Healthcare Conference is scheduled for September 28, 2021, with a fireside chat at 10:40 a.m. ET. Webcasts of both events will be available on the Company's Investor Relations website for 90 days post-event, highlighting Codexis' advancements in synthetic biology and enzyme technology.

REDWOOD CITY, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Codexis, inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that management will participate in two upcoming virtual investment conferences.

The H.C. Wainwright 23^rd Annual Global Investment Conference — September 13, 2021 at 7:00 a.m. ET, on-demand corporate presentation

The Cantor Virtual Global Healthcare Conference — September 28, 2021 at 10:40 a.m. ET, fireside chat

Webcasts of the presentations will be available in the Investor Relations section of the Company’s website, http://ir.codexis.com. Replays of the webcasts will be archived for 90 days following their respective presentation dates.

About Codexis
Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver® platform to discover and develop novel, high performance enzymes and novel biotherapeutics. Codexis enzymes have applications in the sustainable manufacturing of pharmaceuticals, food, and industrial products; the creation of the next generation of life science tools; and as biologic therapeutics and in gene therapy. The Company’s unique enzymes drive improvements such as reduced energy usage, waste generation and capital utilization, higher yields, higher fidelity diagnostics, and more efficacious therapeutics. Codexis enzymes enable the promise of synthetic biology to improve the health of people and the planet. For more information, visit www.codexis.com.

Investor Relations Contact:
Argot Partners
Stephanie Marks/Carrie McKim
(212) 600-1902
Codexis@argotpartners.com

 

FAQ

When will Codexis participate in the H.C. Wainwright Annual Global Investment Conference?

Codexis will participate in the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, at 7:00 a.m. ET.

What is the date and time for the Cantor Virtual Global Healthcare Conference?

How can I access the webcasts of Codexis' presentations?

Webcasts of Codexis' presentations will be available in the Investor Relations section of their website for 90 days following the events.

What platform does Codexis use for enzyme development?

Codexis leverages its proprietary CodeEvolver® platform for discovering and developing high-performance enzymes.

What are the applications of Codexis enzymes?

Codexis enzymes have applications in sustainable manufacturing of pharmaceuticals, food, industrial products, and more.